Assessing the benefit–risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer

Cost-effectiveness of systemic therapies for metastatic pancreatic cancer

(2013) V.C. Tam et al.   Current Oncology

Adherence to CONSORT Adverse Event Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: A Systematic Review

(2013) Julien Péron et al.   JOURNAL OF CLINICAL ONCOLOGY

KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer

(2013) Stefan Boeck et al.   JOURNAL OF GASTROENTEROLOGY

Quality of Reporting of Modern Randomized Controlled Trials in Medical Oncology: A Systematic Review

(2012) J. Peron et al.   JNCI-Journal of the National Cancer Institute

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial

(2011) Matthew T Seymour et al.   LANCET

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Health outcomes in economic evaluation: the QALY and utilities

(2010) S. J. Whitehead et al.   BRITISH MEDICAL BULLETIN

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer

(2010) Gilda da Cunha Santos et al.   CANCER

Generalized pairwise comparisons of prioritized outcomes in the two-sample problem

(2010) Marc Buyse   STATISTICS IN MEDICINE

QALYs: The Basics

(2009) Milton C. Weinstein et al.   VALUE IN HEALTH

Reformulating the hazard ratio to enhance communication with clinical investigators

(2008) Marc Buyse   Clinical Trials

Reformulating the hazard ratio to enhance communication with clinical investigators

(2008) Barry K Moser et al.   Clinical Trials